Dr. Leber is a former PhD student in the NIMML, studying Genomics, Bioinformatics, and Computational Biology with a B.S. in biomedical engineering from PSU. Dr. Andrew Leber contributes deep knowledge of immunology, advanced computational modeling, data analytics, AI, and drug development to Landos Biopharma. As the Scientific Director, he is responsible for assessing the therapeutic potential of lead immunoregulatory targets in autoimmune diseases. Dr. Leber’s expertise in immunometabolism helped Landos advance its first-in-class asset for IBD, BT-11, into clinical development.